Jingyu Yu

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond

Lee H. Pai-Scherf, Gideon M. Blumenthal, Hongshan Li et al. · The Oncologist · 2017 · 292 citations · Full text

Medicine, Oncology, Pharmacology +16

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

Erin Larkins, Gideon M. Blumenthal, Weishi Yuan et al. · The Oncologist · 2017 · 216 citations · Full text

Medicine, Oncology, Pharmacology +16

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Elaine Chang, Chana Weinstock, Lijun Zhang et al. · Clinical Cancer Research · 2020 · 183 citations · Full text

Medicine, Oncology, Pharmacology +11

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Preeti Narayan, Tatiana M. Prowell, Jennifer Gao et al. · Clinical Cancer Research · 2020 · 166 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation–Associated Advanced Ovarian Cancer

Sanjeeve Balasubramaniam, Julia A. Beaver, Sara Horton et al. · Clinical Cancer Research · 2017 · 164 citations

Medicine, Gynecology, Oncology +17